Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email publishing@financialexpress.net in the first instance.

 Information  X 
Enter a valid email address

Plethora Solutions (PLE)

  Print      Mail a friend       Annual reports

Friday 15 June, 2012

Plethora Solutions

Issue of Equity - Directors' Interest

RNS Number : 5134F
Plethora Solutions Holdings PLC
15 June 2012
 

 

 

15 June 2012

 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Issue of Equity - Directors' Interest

 

 

Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces that it has made the following share issues.

 

First, 140,000 shares have been issued to the pension fund of Ronald Openshaw, CEO, Plethora Solutions, at 5p per share to satisfy liabilities up to 31 May 2012. Following this issue Mr Openshaw has a beneficial interest in 416,669 shares representing approximately 0.2% of the enlarged issued share capital of the Company.

 

The Company and Mr Openshaw have agreed that on an ongoing basis it will satisfy his pension contributions on a quarterly basis through the issue of new ordinary shares issued at the closing mid-market price on the day before issue. Further issues will be made as soon as practicable following the end of each calendar quarter.  The next issue will be made following the end of the September quarter.  This arrangement will remain in place for a minimum of 12 months and may be terminated, thereafter, by either party following not less 3 months notice and provided that the Company is not in a Close Period as defined by the AIM Rules.

 

Second, 384,000 new shares have been issued to Richard Horsman, non-executive director, in satisfaction of director's fees accrued to him.  Following this issue Mr Horsman has a beneficial interest in 1,077,000 shares representing approximately 0.5% of the enlarged issued share capital of the Company.

 

Finally, the Company has issued 660,000 shares to a professional adviser in satisfaction of part of its fees.

 

Application will be made for the 1,184,000 new shares issued to be admitted to trading on AIM ("Admission"). It is expected that Admission will be effective and trading will commence at 8:00am on 19 June 2012.

 

Following Admission, the Company will have 208,941,531 Ordinary Shares in issue. Since the Company holds no shares in Treasury, the total number of voting rights in the Company is therefore 208,941,531 and this figure may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

 

 

 

-Ends-

 

Enquiries:



Plethora Solutions

Ronald Openshaw, CEO

Tel : +44(0) 20 3077 5400

Daniel Stewart (Nomad & Joint Broker)

David Hart / James Felix (Nomad)

Martin Lampshire (Broker)

Tel : +44(0) 20 7776 6550

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce/ Deepak Reddy

Tel: +44(0) 20 7947 4350

 

Britton Financial PR

Tim Blackston

Tel: +44 (0) 20 7242 9786

       +44 (0) 7957 140416

 

 

About Plethora:

Plethora is focussed on the development and marketing of products for the treatment of urological disorders.

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com

 

Plethora is focussed on: (i) seeking to launchPSD502 for the treatment of premature ejaculation; and (ii) driving the development of its speciality sales and marketing business, The Urology Co.

 

About PSD502 & Premature Ejaculation:

PSD502 is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture.  The product has completed all clinical testing and has been submitted for approval in Europe with the EMA.  The Company anticipates launch in late 2013 or early 2014.

 

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

 

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

 

About The Urology Co:

Plethora's subsidiary, The Urology Co, established in 2009, markets and distributes a range of pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, sexual health, gynaecology and reproductive health conditions. Its products fall into two categories (i) Professional - where a physician, nurse or other healthcare professional makes a prescribing decision and include Gepan® instil, Striant® SR, Urolieve®, Hyalofemme® and Dianatal®; and (ii) Consumer - where the consumer/patient makes a buying decision and include Hyalofemme®, Multi-Gyn®, Multi-Mam® and hI-Cran®.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEELFFLQFBBBV